The agreement grants Daiichi Sankyo worldwide and nonexclusive rights to intellectual property that GlycoT currently licenses from the University of Maryland, Baltimore and University of Maryland, College Park. The deal includes an undisclosed upfront payment, annual fees, and royalties on sales of GlycoT.

The enzymatic glycoengineering technology platform allows scientists to precisely change and modify the sugars on monoclonal antibodies. Daiichi Sankyo plans to use the technology in the development of new drug candidates.

The technology was originally developed by Lai-Xi Wang, PhD, founder and president of GlycoT Therapeutics and professor in the department of chemistry and biochemistry at the University of Maryland, College Park.

Synaffix, ADC Therapeutics collaborate on antibody drug conjugates
Synaffix and ADC Therapeutics have expanded an existing collaboration to explore additional applications of Synaffix's site-specific conjugation technologies.

Pioneering technology stabilizes vaccines at all temperatures
Scientists have identified a new method called ensilication to prevent warmed-up vaccines from degrading. By coating proteins in a silica shell, the structures...

Researchers investigate how a potent mAb blocks SARS-CoV-2
Based on previous research that explored therapies against SARS-CoV, a new report has identified a fully human monoclonal antibody (mAb) that prevents...